CGMP Consulting, Inc.

06/18/2026

Warehouse qualification is a core service. Because of that, we have a well-defined process that is accommodating to any client’s requirements.

Learn more here https://cgmpconsulting.com/services/facility-utility-qualification/

06/17/2026

Every client is different.

We assess what your system needs and create the scope accordingly. That is how we protect your budget and your timeline.

Contact us today at https://cgmpconsulting.com/contact-us/.

06/12/2026

Is your warehouse ready? Summer temperatures won’t wait for your qualification schedule.

If your facility has not completed its warehouse qualification, now is the time to act.

Contact us today to schedule your warehouse qualification before the summer season is upon us and learn more here: https://cgmpconsulting.com/services/facility-utility-qualification/

06/10/2026

Our people are our product.

We are proud to share that 96.4% of cGMP Consulting staff members would recommend this organization as a great place to work; a result of our 2026 Annual Employee Engagement Survey.

When our people feel valued and invested in what we do, that commitment flows directly to our clients.

Thank you to our team!

https://cgmpconsulting.com/careers/

06/09/2026

Continuing our FDA Form 483 series: Medical Devices.

After a dip in FY2024, device sector observations rebounded sharply to 791 in FY2025, an 18% increase and the highest total in three years.

The top 5 citation categories:

1. Lack of or inadequate procedures (21 CFR 820.100(a)) — 279 observations

2. Lack of or inadequate complaint procedures (21 CFR 820.198(a)) — 211 observations

3. Purchasing controls (21 CFR 820.50) — 115 observations

4. Nonconforming product procedures (21 CFR 820.90(a)) — 95 observations

5. Lack of or inadequate process validation (21 CFR 820.75(a)) — 93 observations



The top two citations alone account for nearly 500 observations. Complaint handling is a particular concern. It is one of the most direct windows FDA has into how a device company responds to real-world product performance. Gaps there tend to draw significant attention.

cGMP Consulting helps medical device manufacturers build and strengthen quality systems under 21 CFR Part 820.

06/05/2026

The cGMP Consulting team had a fantastic time at our Summer Picnic yesterday evening! It was a beautiful, sunny day filled with delicious food, fun games, and great company. From co****le and spikeball to badminton, there was plenty of friendly competition and laughter. A big thank you to everyone who joined us and helped make it such a memorable event!

06/03/2026

Non-conformance/Deviation, CAPA and Change control are three tools every quality team needs and can be confusing for those new to Quality Management Systems.

Our latest article breaks down what each one does, when to use it, and how they work together in a GMP-compliant Quality Management System. We also answer the questions we hear most often from teams building or strengthening their QMS programs.

This is a practical resource worth bookmarking.

Read the full article:

Learn the differences between non-conformances, CAPA, and change control in GMP quality systems.

06/02/2026

Continuing our FDA Form 483 series: Drugs.

Drug manufacturing saw 713 observations in FY2025, a 27% jump from 561 in FY2024. That's the highest drug sector total in three years.



So what is FDA finding most often? The top 5 citation categories are shown in this graphic.

1. Written procedures not followed (21 CFR 211.22(d)) — 243 observations

2. Investigations of discrepancies and failures (21 CFR 211.192) — 164 observations

3. Absence of written procedures (21 CFR 211.100(a)) — 162 observations

4. Laboratory controls not scientifically sound (21 CFR 211.160(b)) — 121 observations

5. Cleaning, sanitizing and maintenance (21 CFR 211.67(a)) — 95 observations



Two of the top three citations are about written procedures. Either they don't exist, or they aren't being followed.

It’s not uncommon for facilities to invest in equipment and processes but underinvest in the quality systems that document and govern them.

https://cgmpconsulting.com/services/regulatory-response/

05/29/2026

The FDA has released new guidance on responding to Form 483 observations at the conclusion of a drug cGMP inspection and it's worth a careful read.

Recently, we have shared Form 483 trends the top observations across industries. This guidance formalizes what the Agency expects from manufacturers when observations are issued: timely, substantive responses that demonstrate genuine understanding of the underlying issue.

Key takeaways:
• The FDA distinguishes between responses that acknowledge an observation and those that demonstrate corrective action with adequate supporting evidence
• Vague commitments to update procedures are unlikely to satisfy reviewers
• Root cause analysis and implementation timelines carry significant weight

This guidance warrants a full read from your quality and regulatory teams.

05/27/2026

Continuing our FDA Form 483 series: Biologics.

Of all the sectors we're covering, biologics had the most dramatic change in FY2025. Observations jumped from 49 to 110, a 124% increase in a single year.

So what is FDA finding? The graphic shows the five most common observations.
1. SOP compliance (21 CFR 606.100(b)) — 38 observations
2. Required records (21 CFR 606.160(b)) — 19 observations
3. Thorough investigations (21 CFR 606.100(c)) — 18 observations
4. Concurrent documentation (21 CFR 606.160(a)(1)) — 16 observations
5. Emergency transfusion records (21 CFR 606.151(e)) — 14 observations

Notice that each of these is a documentation or recordkeeping failure. FDA inspectors are consistently finding that the paperwork isn't keeping pace with the complex science of this industry.

https://cgmpconsulting.com/services/regulatory-response/